What is HC Wainwright’s Forecast for DMAC FY2029 Earnings?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Research analysts at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for DiaMedica Therapeutics in a report issued on Wednesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of $0.14 for the year, down from their previous estimate of $0.15. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ FY2030 earnings at $0.56 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Monday, March 30th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.03) million during the quarter, compared to analysts’ expectations of $13.50 million.

A number of other equities analysts also recently weighed in on DMAC. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $12.33.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $6.48 on Thursday. DiaMedica Therapeutics has a one year low of $3.19 and a one year high of $10.42. The company’s 50-day simple moving average is $7.80 and its 200 day simple moving average is $7.64. The firm has a market capitalization of $349.14 million, a P/E ratio of -9.26 and a beta of 1.16.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada raised its holdings in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after buying an additional 154,701 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of DiaMedica Therapeutics by 76.7% during the first quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after buying an additional 52,854 shares during the last quarter. Jane Street Group LLC increased its position in shares of DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock valued at $382,000 after acquiring an additional 58,457 shares in the last quarter. Geode Capital Management LLC raised its holdings in DiaMedica Therapeutics by 99.6% in the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after acquiring an additional 314,407 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in DiaMedica Therapeutics in the 2nd quarter worth approximately $56,000. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.